Flinton Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Flinton Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-34	Closed	-$3K	–	893
2019 Q1	$3K	Buy	+34	New	+$2.89K	﹤0.01%	872

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Flinton Capital Management's XBI Position: Q2 2019 in Review

Flinton Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2019, closing a stake of 34 shares — an estimated $3K sold.

Flinton Capital Management first reported a position in XBI in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 424 funds tracked by Wall St. Rank hold XBI as of Q2 2019.

Flinton Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2019 after selling out during the quarter.
Flinton Capital Management sold 34 State Street SPDR S&P Biotech ETF shares in Q2 2019, an estimated $3K.
Flinton Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and held it in 1 quarter.
Flinton Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3K in Q1 2019.
424 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2019.

Based on Flinton Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.